UBS Upgrades Biogen to Buy, Raises Price Target to $225

Benzinga Newsdesk www.benzinga.com Positive 79.6%

Neg 0% Neu 0% Pos 79.6%

UBS analyst Michael Yee upgrades Biogen (NASDAQ:BIIB) from Neutral to Buy and raises the price target from $185 to $225.